HC Wainwright initiated coverage on shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) in a report issued on Tuesday morning, Marketbeat reports. The brokerage issued a buy rating and a $30.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Adverum Biotechnologies’ Q1 2024 earnings at ($1.23) EPS, Q2 2024 earnings […]
Adverum Biotechnologies (NASDAQ:ADVM – Free Report) had its target price trimmed by Mizuho from $40.00 to $22.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other research analysts also recently issued reports on the company. StockNews.com raised Adverum Biotechnologies […]
StockNews.com upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM – Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday. A number of other equities analysts have also recently commented on ADVM. Mizuho lifted their price target on Adverum Biotechnologies from $20.00 to $40.00 and gave the stock […]
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability. Profitability This table compares Adverum Biotechnologies and Agenus’ […]
Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability. Risk and Volatility Adverum Biotechnologies has a beta […]